Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN) - Tabular View

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)

This study has been withdrawn prior to recruitment.

Study NCT00704951. Last updated on November 24, 2008. Information provided by Schering-Plough

This Tabular View shows the required WHO registration data elements as marked by ^†

Descriptive Information Fields
Brief Title ^†	Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)
Official Title ^†	P05532 Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections (IFIs) in Immuncompromised Patients in Austria. Version 1, 08-Nov-2007.
Brief Summary	The purpose of this program is to determine the frequency of the use of Posaconazole in immunocompromised patients refractory to first line therapy receiving therapeutic treatment based on different pathogens in comparison to other antifungal therapy. A further objective is to determine the frequency of the use of Posaconazole in immunocompromised patients receiving prophylactic treatment in comparison to other antifungal prophylaxis.
Detailed Description
Study Phase
Study Type ^†	Observational
Study Design ^†	Cohort, Prospective
Primary Outcome Measure ^†	Safety: adverse events [ Time Frame: Depending on treatment modality every 2 to 4 weeks ] [ Designated as safety issue: Yes ]
Secondary Outcome Measure ^†	Baseline: Patient demographic data; Disease history; Underlying diseases; Diagnosis; Previous therapies; Environmental risk factors; Host factors Performance status [ Time Frame: Depending on treatment modality every 2 to 4 weeks ] [ Designated as safety issue: No ] Treatment and follow up period: Performance status; Medication; Duration of treatment; Frequency of infectious episodes; Management of infections [ Time Frame: Depending on treatment modality every 2 to 4 weeks ] [ Designated as safety issue: No ] Adverse events; Survival status [ Time Frame: Depending on treatment modality every 2 to 4 weeks ] [ Designated as safety issue: Yes ]
Condition ^†	Mycoses
Intervention ^†	Drug: Posaconazole or alternative fungal treatment
MEDLINE PMIDs
Links

Recruitment Information Fields
Recruitment Status ^†	Withdrawn
Enrollment ^†	250
Start Date ^†	July 2008
Completion Date	June 2011
Eligibility Criteria ^†	Inclusion Criteria: Immunocompromised patients with refractory IFI Patients eligible for prophylactic treatment due to anticipated neutropenia for more than 7 days. Exclusion Criteria: None
Gender	Both
Ages
Accepts Healthy Volunteers	No
Contacts ^††
Location Countries ^†

Administrative Information Fields
NCT ID ^†	NCT00704951
Organization ID	P05532
Secondary IDs ^††
Study Sponsor ^†	Schering-Plough
Collaborators ^††
Investigators ^†
Information Provided By	Schering-Plough
Verification Date	November 2008
First Received Date ^†	June 23, 2008
Last Updated Date	November 24, 2008

^† Required WHO trial registration data element.
^†† WHO trial registration data element that is required only if it exists.